IP Library › Granted Patent US 12,227,734
Granted Patent B2
US 12,227,734 · App. 17/837,772 · Granted Feb 18, 2025

Microscale bioprocessing system and method for protein manufacturing from human blood

Inventors: Govind Rao (Ellicott City, MD); Yordan Kostov (Columbia, MD); Leah Tolosa Croucher (Columbia, MD); Kevin Tran (Marriotsville, MD); Monohar Pilli (Gwynn Oak, MD); Michael Tolosa (Columbia, MD); Chandrasekhar Gurramkonda (Halethorpe, MD); David Burgenson (Daly City, CA)
Assignee: University of Maryland, Baltimore County
C12M47/12A61K35/14A61M1/3621B01D15/08B01D15/327B01D15/361B01D15/3847C07K1/36C12M21/18C12M29/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,227,734
App. No.
17/837,772
Granted
Feb 18, 2025
Kind
B2
Abstract

A bioprocessing system for protein manufacturing from human blood is provided that is compact, integrated and suited for on-demand production and delivery of therapeutic proteins to patients. The parent's own blood can be used as the source of cell extracts for the production of the therapeutic proteins.

Claims (28)

1. A system for expressing and purifying a desired protein from blood, comprising:

a whole blood separator adapted for receiving whole blood and outputting (i) at least one blood fraction comprising at least one of erythrocytes, reticulocytes and lymphocytes and (ii) a plasma and unused portion fraction;

a blood cell lysing module adapted for receiving and lysing the at least one blood fraction from the whole blood separator and outputting a lysate;

a bioreactor, adapted for producing the desired protein utilizing cell-free protein expression, for receiving the lysate from the blood cell lysing module and producing the desired protein from the lysate via protein expression utilizing cDNA or mRNA for the desired protein; and

a purification module for receiving the desired protein from the bioreactor and purifying the desired protein.

2. The system of claim 1 , wherein the bioreactor has a capacity of 20 ml or less.

3. The system of claim 1 , further comprising a diafiltration component for receiving the purified desired protein from the purification module and for further purifying the desired protein.

4. The system of claim 3 , wherein the diafiltration component comprises: a product section for receiving purified desired protein from the purification module; and a buffer section for receiving a buffer solution.

5. The system of claim 4 , wherein the diafiltration component comprises:

a first substrate;

a second substrate; and

a diafiltration membrane positioned between the first and second substrates.

6. The system of claim 5 , wherein the diafiltration component further comprises

a flow cell; and

tubing positioned within the flow cell, wherein the diafiltration membrane comprises the tubing material.

7. The system of claim 1 , wherein the desired protein comprises a therapeutic protein and wherein the whole blood originates from a patient to whom the therapeutic protein will be administered.

8. The system of claim 5 , wherein the product section comprises a serpentine-shaped channel formed on the first substrate and the buffer section comprises a serpentine-shaped channel formed on the second substrate, wherein the first and second serpentine-shaped channels substantially correspond with each other.

9. The system of claim 1 , wherein the blood cell lysing module comprises at least one lysing reagent comprising EDTA.

10. The system of claim 1 , wherein the bioreactor further comprises a fluid storage/dispenser comprising at least one container selected from the group consisting of a holding container, a washing solution container, a lysing reagent container, a reaction solution container, and a buffer container.

11. The system of claim 1 , wherein the purification module comprises one of membrane chromatography or column chromatography.

12. The system of claim 1 , wherein the bioreactor further comprises at least one optical chemical sensor positioned inside the bioreactor.

13. The system of claim 1 , further comprising a first heating and cooling element positioned inside the bioreactor for controlling a temperature solution inside the bioreactor.

14. The system of claim 1 , wherein the system further comprises a processor for controlling and/or monitoring the bioreactor and the purification module.

15. The system of claim 1 , wherein the bioreactor further comprises a DNA port.

16. The system of claim 1 , wherein the lysate is cell-free.

17. The system of claim 1 , wherein the system further comprises a plasma and unused portion container in fluid communication with both the whole blood separator and a coupling unit, wherein the plasma and unused portion fraction is temporarily stored in the plasma and unused portion container.

18. The system of claim 17 , wherein the coupling unit is in fluid communication with either the purification module or, when present, a diafiltration component, for combining the purified desired protein with the plasma and unused portion fraction.

19. The system of claim 1 , wherein the blood cell lysing module comprises at least one of a mechanical lysis device, an osmotic shock lysis device, a high pressure shock lysis device or an electroporation lysis device.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2025
From: RAO, GOVIND; KOSTOV, YORDAN; TOLOSA, LEAH; TRAN, KEVIN; PILLI, MONOHAR; TOLOSA, MICHAEL; GURRAMKONDA, CHANDRASEKHAR; BURGENSON, DAVID
To: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
Reel/Frame 069778/0126 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2025
From: TOLOSA CROUCHER, LEAH
To: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
Reel/Frame 069787/0934 →
Continuity (3)
Continuation 15329555
Provisional Application 62031484 · Jul 31, 2014
Related Publication 20220298469A1 · Sep 22, 2022
References Cited (38)
US 4156681A · Schneider et al. · 1979 [cited by applicant]
US 4303193A · Latham, Jr. · 1981 [cited by applicant]
US 5112949A · Vukovich · 1992 [cited by applicant]
US 5785869A · Martinson et al. · 1998 [cited by applicant]
US 5968767A · Sheikh et al. · 1999 [cited by applicant]
US 6642024B1 · Pennica · 2003 [cited by applicant]
US 6670173B1 · Schels et al. · 2003 [cited by applicant]
US 6673532B2 · Rao · 2004 [cited by applicant]
US 6905843B1 · Endo et al. · 2005 [cited by applicant]
US 6946075B2 · Kopf · 2005 [cited by applicant]
US 7041493B2 · Rao · 2006 [cited by applicant]
US 7485454B1 · Jury et al. · 2009 [cited by applicant]
US 9163272B2 · Park et al. · 2015 [cited by applicant]
US 9388373B2 · Rao · 2016 [cited by applicant]
US 9982227B2 · Rao et al. · 2018 [cited by applicant]
US 10435664B2 · Rao · 2019 [cited by applicant]
US 20080248521A1 · Knapp et al. · 2008 [cited by applicant]
US 20080269468A1 · Vogel et al. · 2008 [cited by applicant]
US 20080287656A1 · Peters et al. · 2008 [cited by applicant]
US 20090178495A1 · Steigmiller et al. · 2009 [cited by applicant]
US 20100298172A1 · Desmond et al. · 2010 [cited by applicant]
US 20110065084A1 · Rao et al. · 2011 [cited by applicant]
US 20120024788A1 · Kelso et al. · 2012 [cited by applicant]
US 20130280797A1 · Rao et al. · 2013 [cited by applicant]
EP 1775000 · 2007 [cited by applicant]
EP 2302407 · 2011 [cited by applicant]
WO WO2005063808 · 2005 [cited by applicant]
WO WO2008066583 · 2008 [cited by applicant]
WO WO2016019350 · 2016 [cited by applicant]
Waters et al. (2013). A Practical and Novel Method to Extract Genomic DNA from Blood Collection Kits for Plasma Protein Preservation. Journal of Visualized Experiments. p. 1-6. [cited by examiner]
Bank et al., Protein synthesis in a cell free human reticulocyte system: ribosome function in thalassemia. J Clin Invest. Mar. 1966;45(3):330-6. [cited by applicant]
Calhoun et al., Energy Systems for ATP Regeneration in Cell-Free Protein Synthesis Reactions, in: In Vitro Transcription and Translation Protocols, 2nd edition, Guido Grandi ed., 2007 Humana Press Inc., New Jersey. 23 p… [cited by applicant]
Extended European Search Report issued in EP application No. 15827147.8 on Feb. 20, 2018. [cited by applicant]
Office Action issued in Canadian patent application No. 2956924, Oct. 30, 2018. 4 pp. [cited by applicant]
Office Action, U.S. Appl. No. 16/660,993; Dated Apr. 15, 2020. 13 pages. [cited by applicant]
Pierce. Protein stability and Storage, Technical resource, 2005, updated Jul. 14, 2015. pp. 1-3. [cited by applicant]
Salehi et al., Cell-free protein synthesis of a cytotoxic cancer therapeutic: Onconase production and a just-add-water cell-free system. Biotechnol J. Feb. 2016;11(2). 24 pages. [cited by applicant]
Sun et al., Protein degradation in a TX-TL cell-free expression system using ClpXP protease. TechnicalReport, Jul. 8, 2014, http://www.cds.caltech.edu/˜murray/papers/sksm14-clpxp.html . 11 pages. [cited by applicant]